



Please complete as many details as possible and forward within one business day to:

**Program Details**

|  |   |
|--|---|
| Name of Program: HCV Elimination Project                                       | Form Completed By                       |
| Name of Organisation: Ministry of Labour, Health and Social Affairs of Georgia | Print Name: Giorgi Khatelishvili        |
| Date aware of Safety Information: 26/11/15                                     | Signature:                              |
| Country of Occurrence of Safety Information: Georgia                           | Telephone Number: +995598708807         |
|  | Fax No/Email: Gkhatelishvili@moh.gov.ge |

**Patient Details**

|         |              |   |                                     |
|---------|--------------|---|-------------------------------------|
| Age: 58 | Initials: MD | Sex: Male <input checked="" type="checkbox"/> Female <input type="checkbox"/> | DOB: 03-03 (or year of birth): 1957 |
|---------|--------------|---|-------------------------------------|

**Drug Details** (Provide additional drugs on a separate page)

| Drug Name | Dose  | Route | Start Date (DD/MON/YYYY) | Stop Date (or On-going) (DD/MON/YYYY) | Reason For Taking | Lot/Batch No |
|-----------|-------|-------|--------------------------|---------------------------------------|-------------------|--------------|
| Sovaldi   | 400mg | PO    | 02-10-2015               | 26-10-2015                            | Chronic Hep C     | SFMTD        |
| Ribavirin | 200mg | PO    | 02-10-2015               | 26-10-2015                            | Chronic Hep C     |              |
| INF       | 180mg | INJ   | 02-10-2015               | 26-10-2015                            | Chronic Hep C     |              |

**Safety Information Details:** Please provide a short summary of the adverse event(s) (AE) or other safety information (e.g. reports such as pregnancy, death, hospitalization, overdose, misuse, abuse, medication error, lack of effect, off-label use, occupational exposure, AEs associated with product complaints or AEs in an infant following exposure from breastfeeding). Please include the start and stop dates and the outcome of the event(s) or confirm if the event(s) is/are still ongoing. Please also provide any treatment given to treat the event(s), any relevant medical history and for reports of death include the date of death – continue on another page if necessary.

SAE, Death reason Bleeding from esophageal varices

|   |   |
|---|---|
| Does the Reporter consider that the event(s) were possibly related to the drug? Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> | Has this safety information previously been reported to a Regulatory Authority? Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> |
|---|---|

**Reporter Details** (i.e. who notified you of the above safety information?)

|  |                    |
|--|--------------------|
| Is the Reporter a: Doctor <input type="checkbox"/> Nurse <input type="checkbox"/> Pharmacist <input type="checkbox"/> Non-healthcare professional (e.g. patient, relative)* <input type="checkbox"/> |                    |
| <i>If the Reporter is a Healthcare Professional (HCP) and they are willing to provide us with their contact information, please record below</i>   |                    |
| <i>*If the Reporter is a Non-healthcare professional, please confirm if they are willing to provide contact information for their HCP:</i>   |                    |
| Yes <input type="checkbox"/> (Please record HCP details below) No <input type="checkbox"/>   |                    |
| HCP Name:  | <b>HCP Address</b> |
| HCP Telephone No/FAX No:   | First Line:        |
| HCP Email:   | Town/City:         |
|  | County/State:      |
|  | Postcode/Zip code: |

Please be aware that information provided to Gilead relating to you, may be used to comply with applicable laws and regulations. By providing us with information you are consenting to the control and processing of this personal or sensitive data by Gilead in accordance with applicable data protection laws and the Gilead privacy policy, available to you either on [www.gilead.com/privacy](http://www.gilead.com/privacy) or upon request.